HC Wainwright Analysts Give Keryx Biopharmaceuticals (NASDAQ:KERX) a $9.00 Price Target
HC Wainwright set a $9.00 price target on Keryx Biopharmaceuticals (NASDAQ:KERX) in a report issued on Thursday, August 23rd. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
“Our therapeutic models are patient-based and reflect our assumptions for the market size and share penetration rates and pricing. We use this to determine the future revenue streams. These metrics then flow into our valuation model.”,” the firm’s analyst commented.
A number of other equities research analysts have also issued reports on KERX. ValuEngine raised Keryx Biopharmaceuticals from a strong sell rating to a sell rating in a research note on Wednesday, May 2nd. Maxim Group set a $9.00 price objective on Keryx Biopharmaceuticals and gave the stock a buy rating in a report on Thursday, May 10th. BidaskClub upgraded Keryx Biopharmaceuticals from a hold rating to a buy rating in a report on Saturday, May 12th. Stifel Nicolaus restated a hold rating and set a $5.00 price objective on shares of Keryx Biopharmaceuticals in a report on Monday, June 25th. Finally, Zacks Investment Research upgraded Keryx Biopharmaceuticals from a hold rating to a buy rating and set a $4.50 price target on the stock in a report on Tuesday, July 10th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $6.25.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). analysts forecast that Keryx Biopharmaceuticals will post -0.61 earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of KERX. MetLife Investment Advisors LLC acquired a new stake in Keryx Biopharmaceuticals during the 4th quarter worth about $187,000. Russell Investments Group Ltd. acquired a new position in shares of Keryx Biopharmaceuticals in the 1st quarter valued at about $201,000. Meridian Wealth Management LLC acquired a new position in shares of Keryx Biopharmaceuticals in the 1st quarter valued at about $203,000. Mackay Shields LLC acquired a new position in shares of Keryx Biopharmaceuticals in the 1st quarter valued at about $294,000. Finally, Summit Trail Advisors LLC lifted its holdings in shares of Keryx Biopharmaceuticals by 355.3% in the 1st quarter. Summit Trail Advisors LLC now owns 333,803 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 260,485 shares during the period. 59.53% of the stock is owned by hedge funds and other institutional investors.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Further Reading: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.